Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.61 |
| ▸ | CREBBP | Q92793 | 11/20 | 0.58 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.53 |
| ▸ | WNT3A | P56704 | 2/20 | 0.49 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4434512 | 0.86 | CREBBP (0.73) | TRPV1CREBBP | |
| SCHEMBL14083021 | 0.85 | CREBBP (0.54) | TRPV1CREBBPMCHR1 | |
| SCHEMBL4424955 | 0.84 | CREBBP (0.58) | TRPV1CREBBPMCHR1WNT3A | |
| SCHEMBL13998316 | 0.84 | TRPV1 (0.64) | TRPV1CREBBP | |
| SCHEMBL5934183 | 0.83 | RAB9A (0.67) | TRPV1MCHR1BAZ2B | |
| SCHEMBL13763379 | 0.82 | TRPV1 (0.51) | TRPV1CREBBP | |
| SCHEMBL4429965 | 0.81 | CREBBP (0.59) | TRPV1CREBBP | |
| SCHEMBL13995926 | 0.81 | TRPV1 (0.50) | TRPV1CREBBP | |
| SCHEMBL4427342 | 0.81 | TRPV1 (0.72) | TRPV1CREBBP | |
| SCHEMBL5304051 | 0.78 | TRPV1 (0.47) | TRPV1CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| EP-2033953-A1 | Vanilloid receptor modulators | Glaxo Group Limited (GB) | 2009-03-11 | — | — | EP | disclosed |
| EP-2033953-A1 | Vanilloid receptor modulators | Glaxo Group Limited (GB) | 2009-03-11 | — | — | EP | disclosed |
| US-20060142333-A1 | Vanilloid receptor modulators | MACDONALD GREGOR J | 2006-06-29 | — | — | US | disclosed |
| EP-1480954-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003068749-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142333-A1 | Vanilloid receptor modulators | TRPV1, NPSR1, TRPV3 | TRPV1 1/4885CREBBP 1594/4885MCHR1 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.